Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aldeyra Therapeu
(NQ:
ALDX
)
3.080
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aldeyra Therapeu
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ALDX
August 04, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Investors
August 03, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Investors
August 03, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
Analyst Ratings for Aldeyra Therapeutics
June 22, 2023
Via
Benzinga
Recap: Aldeyra Therapeutics Q1 Earnings
May 04, 2023
Via
Benzinga
The Law Offices of Frank R. Cruz Announces Investigation of Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Investors
August 03, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
EQUITY ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALDX
August 02, 2023
From
Rosen Law Firm
Via
Business Wire
Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Aldeyra Therapeutics, Inc. (ALDX)
August 01, 2023
From
Robbins LLP
Via
Business Wire
Aldeyra Therapeutics to Participate in SVB Securities Therapeutics Forum
July 06, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX‑2191 in Patients with Retinitis Pigmentosa
June 29, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Patients with Retinitis Pigmentosa
June 28, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics' Chronic Cough Potential Shows Significant Reduction In Cough Frequency Versus Placebo
June 27, 2023
Aldeyra Therapeutics Inc (NASDAQ: ALDX) announced top-line results from the Phase 2 clinical trial of ADX‑629, an investigational new drug administered orally to
Via
Benzinga
Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX‑629 in Patients With Chronic Cough
June 27, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX‑629 in Patients with Chronic Cough
June 26, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
June 23, 2023
From
Aldeyra Therapeutics
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
June 21, 2023
Via
Benzinga
Why Are Aldeyra Therapeutics Shares Plummeting Today
June 21, 2023
Aldeyra Therapeutics Inc (NASDAQ: ALDX) has received a Complete Response Letter from the FDA for the 505(b)(2) New Drug Application (NDA) of ADX-2191 (methotrexate for injection) for
Via
Benzinga
Aldeyra Therapeutics Provides Regulatory Update on ADX-2191
June 21, 2023
From
Aldeyra Therapeutics
Via
Business Wire
Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 15, 2023
Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 281% to $0.8396.
Via
Benzinga
Why Aldeyra Therapeutics Stock Is Trading Higher Today
June 15, 2023
Aldeyra Therapeutics Inc (NASDAQ: ALDX) reported topline results from the Phase 3 INVIGORATE-2 trial of 0.25% reproxalap ophthalmic solution, an investigational new drug, in
Via
Benzinga
Domino's Pizza, Patterson-UTI Energy, JinkoSolar And Other Big Stocks Moving Higher On Thursday
June 15, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 180 points on Thursday. Here are some big stocks recording gains in today’s session. Nikola Corporation (NASDAQ: NKLA) jumped 19.9% to...
Via
Benzinga
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE‑2 Trial in Allergic Conjunctivitis
June 14, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
June 02, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights
May 04, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
May 02, 2023
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
10 Health Care Stocks With Whale Alerts In Today's Session
May 01, 2023
Via
Benzinga
The Week In Charts: 0DTE Options - Too Good To Be True?
April 30, 2023
Zero-days; how Core Methodology can be used in Crypto, with current Crypto and stock market conditions; favorite stock picks.
Via
Talk Markets
Short Volatility Alert: Aldeyra Therapeutics
April 28, 2023
On Thursday, shares of Aldeyra Therapeutics (NASDAQ: ALDX) experienced volatile short activity. After the activity, the stock price went down -0.22% to $9.05. The overall sentiment for ALDX has been...
Via
Benzinga
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay
April 18, 2023
Drug development can be notoriously slow, and it can take some companies 10 years or more to pass through all the trials and tests required by the Food and Drug Administration (FDA).
Via
Benzinga
Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis
April 13, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.